{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:25:13Z","timestamp":1790958313695,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jocn.2025.111363","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T15:20:57Z","timestamp":1749136857000},"page":"111363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis"],"prefix":"10.1016","volume":"138","author":[{"given":"Plamen","family":"Penchev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Milanova-Ilieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyubomir","family":"Gaydarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavor","family":"Chenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar-Preslav","family":"Petrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Kirovakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Stanchev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jocn.2025.111363_b0005","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"10.1016\/j.jocn.2025.111363_b0010","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","article-title":"Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study","volume":"44","author":"Beccuti","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1016\/j.jocn.2025.111363_b0015","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jocn.2025.111363_b0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","article-title":"The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study","volume":"22","author":"Ke","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"10.1016\/j.jocn.2025.111363_b0025","article-title":"Impulse control disorders in southern iraqi patients medicated with cabergoline for prolactinoma","volume":"16","author":"Mohammad","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jocn.2025.111363_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101356","article-title":"Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas","volume":"55","author":"Ozkaya","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.jocn.2025.111363_b0035","unstructured":"Higgins J, Thomas J, Chandler J, et al., Hrsg. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org\/handbook."},{"key":"10.1016\/j.jocn.2025.111363_b0040","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2025.111363_b0045","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan \u2014 a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.jocn.2025.111363_b0050","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2025.111363_b0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jocn.2025.111363_b0060","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.jocn.2025.111363_b0065","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/sim.791","article-title":"On tests of the overall treatment effect in meta-analysis with normally distributed responses","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.jocn.2025.111363_b0070","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"10.1016\/j.jocn.2025.111363_b0075","unstructured":"Review Manager (RevMan). Version (version number). The Cochrane Collaboration, (version date). Available at revman.cochrane.org."},{"key":"10.1016\/j.jocn.2025.111363_b0080","unstructured":"Trial Sequential Analysis (TSA) [Computer program]. Version 0.9.5.10 Beta. The Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2013 Rigshospitalet, 2021."},{"issue":"3","key":"10.1016\/j.jocn.2025.111363_b0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.jocn.2025.111363_b0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0028-3886.370452","article-title":"Impulse control disorders with short-term use of cabergoline in macroprolactinomas: a prospective study with a brief review of literature","volume":"71","author":"Sanjan","year":"2023","journal-title":"Neurol India"},{"issue":"1","key":"10.1016\/j.jocn.2025.111363_b0095","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.jocn.2025.111363_b0100","first-page":"1089","article-title":"Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy","volume":"23","author":"Hamidianjahromi","year":"2022","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825003352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825003352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T05:48:10Z","timestamp":1755496090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825003352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"alternative-id":["S0967586825003352"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111363","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111363"}}